We are a seed-stage biotech company dedicated to relentlessly pursuing functional cures for rare disease patients and their families. With an initial focus on rare diseases, we aim to expand our scope to include genetically defined common diseases in the future.

Jantar is a clinical R/D company in the field of chronic rhinosinusitis. Its asset is dicholine succinate for which clinical proof-of-concept has been established. DISU represents a differentiated new drug with strong safety, rapid efficacy and clear potential for global consumer health leadership.

We are a leading international company offering end-to-end solutions ranging from the automation, process engineering and validation of biotech and pharmaceutical plants. With more than two decades of experience in GMP environments, we have in-depth knowledge of the applicable regulations.